EFFECTS OF A NEUTRAL ENDOPROTEASE ENZYME INHIBITOR, THIORPHAN, ON HEMODYNAMICS AND RENAL EXCRETORY FUNCTION IN FOUR MODELS OF EXPERIMENTAL HYPERTENSION

• Published in: Clinical and experimental hypertension (1993) 2000, Vol.22 (1), p.45-62
• Main Authors: Pamnani, Motilal B., Chen, Shanwan, Bryant, Howard J., Schooley, James F., Haddy, Francis J., Ghai, Raj D.
• Format: Article
• Language: English
• Subjects: 1 Clip hypertension; 1-Kidney; 2-Kidney; Animals; Antihypertensive agents; Atrial Natriuretic Factor - blood; Atrial natriuretic peptide; Biological and medical sciences; Biomarkers - blood; Biomarkers - urine; Blood Pressure - drug effects; Cardiovascular system; Cyclic GMP - urine; Hypertension; Hypertension - drug therapy; Hypertension - metabolism; Infusions, Intravenous; Kidney - drug effects; Male; Medical sciences; Neutral endoprotease inhibitor; Pharmacology. Drug treatments; Potassium - urine; Protease Inhibitors - pharmacology; Rats; Rats, Inbred SHR; Reduced renal mass-saline hypertension; SHR; Sodium - urine; Thiorphan; Thiorphan - pharmacology; Urodynamics - drug effects
• ISSN: 1064-1963; 1525-6006
• DOI: 10.1081/CEH-100100061

Thiorphan, a neutral endoprotease (NEP) enzyme inhibitor, has been shown to enhance the effects of atrial natriuretic peptide (ANP) in vivo. In this study, we examined the effects of an intravenous (iv) infusion of thiorphan on cardiovascular hemodynamics and excretion of urine volume (UV), sodium (UNaV) and potassium (UKV) in four different models of experimental hypertension, namely: 1) SHR, 2) two-kidney, one clip (2K1C), 3) one-kidney, 1 clip (1K1C) and, 4) 70% reduced renal mass-salt (RRM-S) hypertensive rats. SHR has normal plasma renin activity, 2K1C is renin dependent, and 1K1C and RRM-S are low renin volume dependent models of hypertension. Rats were divided into experimental and control groups. Under inactin (120 mg kg, body weight) anesthesia, rats were instrumented to record blood pressure and dP dt (Millar catheter) and urine was collected through a suprapubic urinary bladder catheter. Experimental animals received an iv infusion of thiorphan, 0.5 mg kg min for 120 minutes. Control animals received vehicle only. In some animals, vascular smooth muscle cell membrane potentials (Em) was measured in vivo. In another series of experiments, using the identical protocol, cardiac output was recorded. The thiorphan infusion produced a similar progressive decrease in blood pressure in all models of hypertension. Cardiac output did not change relative to vehicle infused control animals. Thus pressure decreased because of a decrease in total peripheral resistance. The contractility index (dP dt P, where P = left ventricular pressure) did not change but vascular smooth muscle cells in tail arteries hyperpolarized in all four models. In spite of a significant decrease in blood pressure, thiorphan infusion either increased or produced no change in urinary volume (UV) and sodium (UNaV) excretion. These data show that thiorphan, an NEP inhibitor, decreases the blood pressure of hypertensive rats due to a decrease in total peripheral resistance, perhaps by hyperpolarizing vascular smooth muscle cells. These effects are independent of the mechanism of the hypertension. Increased UV and UNaV in the face of decreased pressure suggests a direct renal effect.